NCT03801525Phase 2, phase 3Terminated

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

Study sponsor: TG Therapeutics, Inc. · TGTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2022-12-20Actual
Enrollment · participants277Actual
Source updated2024-04-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview